نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

Journal: :Biometrics 2006
Dean Follmann

This article introduces methods for use in vaccine clinical trials to help determine whether the immune response to a vaccine is actually causing a reduction in the infection rate. This is not easy because immune response to the (say HIV) vaccine is only observed in the HIV vaccine arm. If we knew what the HIV-specific immune response in placebo recipients would have been, had they been vaccina...

2014
Georgia D. Tomaras Barton F. Haynes

Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 50...

2010
Eric S. Rosenberg Barney S. Graham Ellen S. Chan Ronald J. Bosch Vicki Stocker Janine Maenza Martin Markowitz Susan Little Paul E. Sax Ann C. Collier Gary Nabel Suzanne Saindon Theresa Flynn Daniel Kuritzkes Dan H. Barouch

BACKGROUND An effective therapeutic vaccine that could augment immune control of HIV-1 replication may abrogate or delay the need for antiretroviral therapy. AIDS Clinical Trials Group (ACTG) A5187 was a phase I/II, randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of an HIV-1 DNA vaccine (VRC-HVDNA 009-00-VP) in subjects treated with antiretroviral ...

2017
D. M. Brett-Major T. A. Crowell N. L. Michael

Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed...

Journal: :Canadian journal of public health = Revue canadienne de sante publique 2000
M P Gagnon G Godin

The aim of this study was to evaluate the acceptability of a hypothetical HIV vaccine and to identify the psychosocial determinants of the intention of receiving HIV immunization, based upon Ajzen's Theory of Planned Behaviour (TPB). Of the 136 young adults surveyed, 120 (88%) had a moderate to high intention to receive the HIV vaccine. A logistic regression was performed and two psychosocial f...

2018
Nicole L Yates Allan C deCamp Bette T Korber Hua-Xin Liao Carmela Irene Abraham Pinter James Peacock Linda J Harris Sheetal Sawant Peter Hraber Xiaoying Shen Supachai Rerks-Ngarm Punnee Pitisuttithum Sorachai Nitayapan Phillip W Berman Merlin L Robb Giuseppe Pantaleo Susan Zolla-Pazner Barton F Haynes S Munir Alam David C Montefiori Georgia D Tomaras

Induction of broadly cross-reactive antiviral humoral responses with the capacity to target globally diverse circulating strains is a key goal for HIV-1 immunogen design. A major gap in the field is the identification of diverse HIV-1 envelope antigens to evaluate vaccine regimens for binding antibody breadth. In this study, we define unique antigen panels to map HIV-1 vaccine-elicited antibody...

Journal: :The Journal of infectious diseases 2011
D W Fitzgerald H Janes M Robertson R Coombs I Frank P Gilbert M Loufty D Mehrotra A Duerr

BACKGROUND The Step study was a randomized trial to determine whether an adenovirus type 5 (Ad5) vector vaccine, which elicits T cell immunity, can lead to control of human immunodeficiency virus (HIV) replication in participants who became HIV-infected after vaccination. METHODS We evaluated the effect of the vaccine on trends in HIV viral load, CD4+ T cell counts, time to initiation of anti...

Journal: :Sexual health 2014
Lars Toft Martin Tolstrup Merete Storgaard Lars Ostergaard Ole S Søgaard

UNLABELLED Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some ...

2017
C. Yong Kang Yong Gao

The development of an efficient prophylactic HIV vaccine has been one of the major challenges in infectious disease research during the last three decades. Here, we present a mini review on strategies employed for the development of HIV vaccines with an emphasis on a well-established vaccine technology, the killed whole-virus vaccine approach. Recently, we reported an evaluation of the safety a...

Journal: :Bulletin of the World Health Organization 1998
R T Perry C V Plowe B Koumaré F Bougoudogo K L Kotloff G A Losonsky S S Wasserman M M Levine

Despite considerable experience with single-dose, live, oral cholera vaccine CVD 103-HgR in Asia, Europe, and the Americas, the vaccine had not been evaluated in sub-Saharan Africa or on individuals infected with human immunodeficiency virus (HIV). We therefore conducted a randomized, placebo-controlled, double-blind, cross-over clinical trial in 38 HIV-seropositive (without clinical acquired i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید